Intensive Monitoring Scheme of Lidocaine Cataplasms
Overview
- Phase
- Not Applicable
- Intervention
- Lidocaine Cataplasms
- Conditions
- Adverse Reaction to Drug
- Sponsor
- Qianfoshan Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).
Investigators
Wei Xu
Principal Investigator
Qianfoshan Hospital
Eligibility Criteria
Inclusion Criteria
- •All patients receiving Lidocaine Cataplasms from January 1, 2021 to April 1, 2022.
Exclusion Criteria
- •Unable to obtain complete medication information.
Arms & Interventions
Patients using Lidocaine Cataplasms
Intervention: Lidocaine Cataplasms
Outcomes
Primary Outcomes
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: January 1, 2021 - April 1, 2022
Past medical history and other diseases that the researcher thinks have clinical significance. Collect the frequency, type, years, etc. of drinking and/or smoking, as well as the family history of diseases. Including white blood cell, red blood cell, hemoglobin, platelet count, etc. Including white blood cells, red blood cells, urine protein, urine sugar, etc. Including ALT, AST, ALP, TBil, GGT, BUN, Cr, etc. The researcher issued a prescription of lidocaine gel plaster according to the drug instructions, and recorded the indications, medication time, dose, frequency, drug batch number, etc. It includes all kinds of reactions unrelated to the treatment purpose during the study period, including symptoms, signs, laboratory abnormalities with clinical significance or special examinations.administration or discharge.